Premium
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study
Author(s) -
Einarson Adrienne,
Maltepe Caroline,
Navioz Yvette,
Kennedy Deborah,
Tan Michael Paul,
Koren Gideon
Publication year - 2004
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2004.00236.x
Subject(s) - ondansetron , nausea , vomiting , pregnancy , medicine , obstetrics , anesthesia , genetics , biology
Objective Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy. Despite the fact that it is not indicated, women are being prescribed this drug for the treatment of nausea and vomiting of pregnancy (NVP). There is a paucity of information on fetal safety for this indication. The objective of this study is to determine whether this drug increases the baseline rate of major malformations. Design A prospective comparative observational study. Setting Teratogen Information Services (TIS). Population Pregnant women. Methods Our three groups included women who were exposed to ondansetron and women exposed to (1) other anti‐emetics and (2) non‐teratogen exposures. All of the women called either our NVP Helpline or TIS at The Motherisk Program in Toronto, Canada, or The Mothersafe Program in Sydney, Australia. Main outcome measure Rates of major malformation. Results We have completed 176 pregnancy outcomes in each group. In the ondansetron cohort, there were 169 live births, 5 miscarriages, 2 therapeutic abortions, 6 (3.6%) major malformations and the mean birthweight was 3362 g [SD 525]. There were no statistical differences in any of the study endpoints between the ondansetron and the comparison groups. Conclusions This drug does not appear (although the sample size is limited) to be associated with an increased risk for major malformations above baseline.